Quantcast
Home > Quotes > GNFT

GENFIT S.A. American Depositary Shares (GNFT) Quote & Summary Data

GNFT 
$24.98
*  
0.12
0.48%
Get GNFT Alerts
*Delayed - data as of Apr. 18, 2019  -  Find a broker to begin trading GNFT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
52
Today's High / Low
$ 24.98 / $ 24.29
Share Volume
91,059
50 Day Avg. Daily Volume
N/A
Previous Close
$ 24.86
52 Week High / Low
$ 26.08 / $ 20.805
Market Cap
969,287,699
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
91,059
50 Day Avg. Daily Volume:
N/A

Trading Range

The current last sale of $24.98 is 20.07% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 24.98 $ 26.08
 Low: $ 24.29 $ 20.805

Company Description (as filed with the SEC)

We are a late-stage clinical biopharmaceutical company dedicated to the discovery and development of innovative drug candidates and diagnostic solutions targeting metabolic and liver-related diseases where there is considerable unmet medical need. We are a leader in the field of nuclear receptor-based drug discovery with a rich history and strong scientific heritage spanning almost two decades. We are evaluating our most advanced drug candidate, elafibranor, in a pivotal Phase 3 clinical trial as a potential treatment for nonalcoholic steatohepatitis, or NASH, and as a potential treatment for primary biliary cholangitis, or PBC. In December 2018, we announced positive preliminary results from our Phase 2 clinical trial in PBC. Our drug discovery efforts are based on selecting appropriate nuclear receptors as targets and utilizing rational drug design to optimize our drug candidates.  ... More ...  



Risk Grade

Where does GNFT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 24.48
Open Date:
Apr. 18, 2019
Close Price:
$ 24.98
Close Date:
Apr. 18, 2019


Consensus Recommendation

Analyst Info